Isomorphic Labs、AI創薬のために$2.1Bを調達
Alphabet傘下のIsomorphic Labsは、Thrive Capitalが主導するシリーズBラウンドで$2.1Bを調達し、AIが生成した創薬候補を臨床試験へ進める。
alphabet subsidiary isomorphic labs secured $2.1 billion in series b funding co-led by thrive capital to scale its ai-driven drug discovery platform. the capital injection aims to advance the company's pipeline of therapeutics into clinical trials and support global hiring efforts for its isodde ai system. founder demis hassabis stated the technology has proven itself and focuses on the mission to solve all disease. this funding reinforces the viability of ai in biotech, bolstering existing collaborations with major pharmaceutical firms like novartis, lilly, and johnson & johnson.